Compare Ecolab Inc. (ECL) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ecolab Inc. vs ResMed Inc. — how do they compare? Ecolab Inc. trades at $278.25 (market cap $79.79B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: Ecolab Inc. is far larger — about 2.4× ResMed Inc.'s market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals.
| ECL | RMD | |
|---|---|---|
Market Cap | $79.79B | $32.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $308.35 | $293.73 |
52-Week Low | $245.73 | $182.82 |
Enterprise Value | $88.57B | $31.97B |
Dividend Yield | 1.03% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ecolab Inc. (ECL) trades at $278.02, down 2.24% on the day, with a bullish technical outlook supported by moving averages. The company reported strong Q2 2026 earnings, beating EPS estimates with $2.09 versus $2.08 expected, driven by 5% organic sales growth. Recent acquisition of CoolIT for $4.75 billion strengthens its AI cooling portfolio. Valuation ratios are elevated, with a P/E of 38.21 and P/S of 4.8, reflecting premium pricing for its consistent profitability and market position.
The outlook remains positive with a consensus price target of $327.90, implying 18% upside, supported by 78% analyst buy ratings. Key risks include high valuation sensitivity to earnings misses, as seen in Q1 2026, and rising input costs pressuring margins. Long-term growth is underpinned by digital expansion and high-tech segment strength, but investors should monitor execution on guidance and macroeconomic pressures on industrial demand.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ecolab Inc.
Ecolab produces and markets cleaning and sanitation products for the hospitality, healthcare, and industrial markets. The firm is the global market share leader in this category with a wide array of products and services, including dish and laundry washing systems, pest control, and infection control products. The company has a strong hold on the U.S. market and is looking to increase its profitability abroad. Additionally, Ecolab serves customers in water, manufacturing, and life sciences end markets, selling customized solutions.
Read more on ECL →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
